Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis
- PMID: 17282996
- DOI: 10.1093/brain/awl371
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis
Abstract
Neuromyelitis optica (NMO) is an inflammatory demyelinating disease that typically affects optic nerves and spinal cord. Its pathogenic relationship to multiple sclerosis (MS) is uncertain. Unlike MS, NMO lesions are characterized by deposits of IgG and IgM co-localizing with products of complement activation in a vasculocentric pattern around thickened hyalinized blood vessels, suggesting a pathogenic role for humoral immunity targeting an antigen in the perivascular space. A recently identified specific serum autoantibody biomarker, NMO-IgG, targets aquaporin-4 (AQP4), the most abundant water channel protein in the CNS, which is highly concentrated in astrocytic foot processes. We analysed and compared patterns of AQP4 immunoreactivity in CNS tissues of nine patients with NMO, 13 with MS, nine with infarcts and five normal controls. In normal brain, optic nerve and spinal cord, the distribution of AQP4 expression resembles the vasculocentric pattern of immune complex deposition observed in NMO lesions. In contrast to MS lesions, which exhibit stage-dependent loss of AQP4, all NMO lesions demonstrate a striking loss of AQP4 regardless of the stage of demyelinating activity, extent of tissue necrosis, or site of CNS involvement. We identified a novel NMO lesion in the spinal cord and medullary tegmentum extending into the area postrema, characterized by AQP4 loss in foci that were inflammatory and oedematous, but neither demyelinated nor necrotic. Foci of AQP4 loss coincided with sites of intense vasculocentric immune complex deposition. These findings strongly support a role for a complement activating AQP4-specific autoantibody as the initiator of the NMO lesion, and further distinguish NMO from MS.
Comment in
-
Complexity and heterogeneity in demyelinating disease.Brain. 2007 May;130(Pt 5):1178-80. doi: 10.1093/brain/awm092. Brain. 2007. PMID: 17472981 No abstract available.
Similar articles
-
Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.Brain. 2007 May;130(Pt 5):1224-34. doi: 10.1093/brain/awm047. Epub 2007 Apr 2. Brain. 2007. PMID: 17405762
-
[AQP4 immunohistochemistry in neuromyelitis optica and multiple sclerosis: a neuropathological review].Brain Nerve. 2010 Sep;62(9):961-74. Brain Nerve. 2010. PMID: 20844307 Review. Japanese.
-
[Neuromyelitis optica and anti-aquaporin 4 antibody--an overview].Brain Nerve. 2008 May;60(5):527-37. Brain Nerve. 2008. PMID: 18516975 Review. Japanese.
-
Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese.Brain. 2007 May;130(Pt 5):1206-23. doi: 10.1093/brain/awm027. Epub 2007 Apr 17. Brain. 2007. PMID: 17439988
-
Neurological autoimmunity targeting aquaporin-4.Neuroscience. 2010 Jul 28;168(4):1009-18. doi: 10.1016/j.neuroscience.2009.08.032. Epub 2009 Aug 20. Neuroscience. 2010. PMID: 19699271 Review.
Cited by
-
Molecular pathogenesis of neuromyelitis optica.Int J Mol Sci. 2012 Oct 11;13(10):12970-93. doi: 10.3390/ijms131012970. Int J Mol Sci. 2012. PMID: 23202933 Free PMC article. Review.
-
Paucity of natural killer and cytotoxic T cells in human neuromyelitis optica lesions.Neuroreport. 2012 Dec 19;23(18):1044-7. doi: 10.1097/WNR.0b013e32835ab480. Neuroreport. 2012. PMID: 23108041 Free PMC article.
-
Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss.Acta Neuropathol. 2012 Jun;123(6):861-72. doi: 10.1007/s00401-012-0986-4. Epub 2012 Apr 22. Acta Neuropathol. 2012. PMID: 22526022 Free PMC article.
-
Is multiple sclerosis an autoimmune disease?Autoimmune Dis. 2012;2012:969657. doi: 10.1155/2012/969657. Epub 2012 May 16. Autoimmune Dis. 2012. PMID: 22666554 Free PMC article.
-
Patient-reported outcome measure for neuromyelitis optica: pretesting of preliminary instrument and protocol for further development in accordance with international guidelines.BMJ Open. 2016 Sep 30;6(9):e011142. doi: 10.1136/bmjopen-2016-011142. BMJ Open. 2016. PMID: 27694484 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical